While most radiomic studies focus on intratumoral regions, recent retrospective studies using peritumoral features have shown utility in breast cancer, such as predicting response to neoadjuvant chemotherapy, human epidermal growth factor receptor 2 (HER2) status, or immune cell infiltration in the TME (18–24). This evidence concerns the gene ERBB2 and breast cancer.